All pharmaceutical companies are facing a major jolt due to recent ban of european union in use of animal models for testing of finished cosmetic products and cosmetic ingredients (european union council directive 76/768/eec). international cooperation on cosmetics regulation (iccr) is strongly encouraging development of alternatives for animal testing and their scientific validation contributing to an ever increasing demand to avoid animal studies due to ethical concern. thus firstly, with our 3d bioprinted scar tissue model, we would target pharmaceutical companies and industries that are in dire need of an ideal testing tool for various drugs and cosmetics for treatment of scar. the developed model will also help in understanding the complex scar pathophysiology providing opportunities for futuristic personalised medicine approach. in that context, establishment of scar models, developed in laboratory by tissue engineering, would play crucial role for studying scar tissue biology, and screening of drugs and cosmetics for the management of scar. secondly, the in vitro scar tissue model can also help to understand the complex pathophysiology of scar by studying the cell-cell and cell-cytokine interactions thus opening new avenues into the understanding of the scar formation. the use of 3d bioprinting technology will provide further edge through precise recapitulation of the in vivo tissue microenvironment and nano-architectural details providing enhanced prospects for cellular attachment, growth and differentiation.
1. Patent filed: S Ghosh, S Chawla, 3D bioprinted scar tissue model: Patent Application Number 201711043083. 2. Manuscript published: Regulation of fibrotic changes by the synergistic effects of cytokines, dimensionality and matrix: towards the development of an in vitro human dermal hypertrophic scar model, S Chawla, S Ghosh, Acta Biomaterialia. Team Member added: Aarushi Sharma, Phd Student (Ist Year).